What it's for (Indications)
- Amlodipine + hydrochlorothiazide + valsartan is a fixed-dose combination medication primarily indicated for the treatment of essential hypertension (high blood pressure) in adult patients.
- This comprehensive combination therapy is specifically employed when monotherapy or dual-combination therapy with one or two of the individual components (amlodipine, hydrochlorothiazide, or valsartan) has proven insufficient in achieving adequate blood pressure control.
- It is also a suitable therapeutic option for patients whose blood pressure is already well-controlled on equivalent doses of the individual components administered as separate tablets, offering the significant benefit of simplified medication regimens and potentially improving patient adherence to a complex treatment plan.
- The rationale behind this triple therapy lies in its ability to target distinct pathophysiological mechanisms involved in blood pressure regulation.
- Amlodipine, a dihydropyridine calcium channel blocker, provides potent peripheral vasodilation; valsartan, an angiotensin receptor blocker, antagonizes the effects of angiotensin II on the renin-angiotensin-aldosterone system; and hydrochlorothiazide, a thiazide diuretic, promotes natriuresis and diuresis, thereby reducing fluid volume.
- This multi-pronged approach allows for robust and comprehensive blood pressure reduction, particularly beneficial in patients with moderate to severe hypertension or those with multiple comorbidities necessitating more aggressive blood pressure management to mitigate the long-term risk of adverse cardiovascular events such as stroke, myocardial infarction, and congestive heart failure.
- The initiation of this combination therapy should always be preceded by a careful assessment of the patient's existing antihypertensive regimen, individual response to components, and overall cardiovascular risk profile, ensuring its appropriate integration into a broader therapeutic strategy for blood pressure management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage should be individualized based on the patient's blood pressure response and tolerability. Consult a healthcare professional for specific dosing instructions. Dose adjustment may be required in patients with liver impairment. No specific dose adjustment is typically required in patients with kidney impairment, but caution is advised. |
Safety & Warnings
Common Side Effects
- Common side effects include headache, edema, fatigue, nausea, dizziness (lightheadedness), flushing (reddening of the skin), rashes, and gingival hyperplasia (overgrowth of gum).
- Less common or rare side effects may include alopecia (spot baldness), pruritus (itching), abdominal pain, back pain, hyperglycemia, increased urination, palpitations, and gastrointestinal (GI) upset.
Serious Warnings
- Black Box Warning: Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus. Specifically, the valsartan component of amlodipine/hydrochlorothiazide/valsartan is associated with significant fetal toxicity. If pregnancy is detected, this medication should be discontinued as soon as possible. Exposure to drugs that act on the RAS during the second and third trimesters of pregnancy has been shown to cause fetal injury including hypotension, renal failure, oligohydramnios, and skeletal deformations, and death. Neonatal adverse effects may include pulmonary hypoplasia, skeletal deformations, and persistent patent ductus arteriosus. Patients of childbearing potential should be advised of the potential risks and to consult their physician immediately if pregnancy is suspected or confirmed. This critical warning underscores the need for careful patient counseling and medication management in women who are or may become pregnant.
- This medicine is not recommended during pregnancy or lactation due to potential fetal harm (especially with the ARB component).
- Exercise caution when driving or operating machinery until individual response to the medication is known.
- Use with caution in patients with liver impairment, as dose adjustment may be required.
- Use with caution in patients with kidney impairment; while no dose adjustment is typically required, clinical monitoring is advisable.
- Alcohol consumption should be avoided.
- Before starting treatment, inform your doctor about your complete medical history, especially any history of heart disease, liver disease, or low blood pressure, and all current medications.
- Do not discontinue this medicine without consulting your doctor, and do not share it with others.
How it Works (Mechanism of Action)
Amlodipine is a dihydropyridine calcium channel blocker (CCB) which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule. Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor in many tissues, including vascular smooth muscle and the adrenal gland.
Commercial Brands (Alternatives)
No other brands found for this formula.